Emcure Pharmaceuticals Expands Poviztra Use for MASH Following CDSCO Approval

On July 20, 2026, Emcure Pharmaceuticals Limited announced the expansion of Poviztra's use for treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults, as per the exchange filing.  

This follows the Central Drugs Standard Control Organization's (CDSCO) approval, marking a significant development in addressing this progressive liver disease. 

CDSCO Approval for MASH Treatment 

On July 20, 2026, Emcure Pharmaceuticals revealed that Poviztra, co-marketed with Novo Nordisk, will be used for MASH treatment in adults with moderate to advanced liver fibrosis (F2-F3).  

The CDSCO's approval of Wegovy for this indication makes it the first GLP-1 receptor agonist approved in India for MASH. 

MASH is linked with obesity, type 2 diabetes, and other metabolic disorders, often remaining asymptomatic until advanced stages.  

The approval is backed by the global Phase III ESSENCE trial, where semaglutide showed resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37%. 

Role of Poviztra in Addressing MASH 

Poviztra contains semaglutide, which has established its role in chronic weight management and is approved for obese patients with cardiovascular disease and adolescent obesity.  

The addition of the MASH indication enhances Emcure's commitment to addressing complex metabolic diseases through innovative therapies. 

Read More: Sun Pharma Share Price in Focus; Receives Nod for Generic Semaglutide in South Africa! 

Emcure's Commitment to Innovation 

Emcure Pharmaceuticals, headquartered in Pune, is a leading Indian pharma company known for its innovation and quality. Established in 1981, it ranks as the 13th largest pharma company in India by domestic sales as of March 2026. Emcure operates in over 70 countries, including Europe and Canada. 

Emcure Pharmaceuticals Share Price Performance 

As of July 20, 2026, at 3:30 PM, Emcure Pharmaceuticals share price on NSE was closed at ₹1,861.20, up by 4.37% from the previous closing price. 

Conclusion 

Emcure Pharmaceuticals' expansion of Poviztra for MASH treatment follows CDSCO approval, supported by the ESSENCE trial results. With 63% resolution of steatohepatitis and 37% improvement in liver fibrosis, this marks a pivotal step in addressing MASH. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Take action on today’s market news - Complete your Demat Account Opening now